Patents by Inventor Clinton Scott Shultz

Clinton Scott Shultz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
    Patent number: 11827614
    Abstract: The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2? inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: November 28, 2023
    Assignees: Merck Sharp & Dohme LLC, Werthenstein Biopharma GMBH
    Inventors: Stephen M. Dalby, Clinton Scott Shultz, Chintal Desai, Joshua Lee, Zhiwei Chen, Jungchul Kim, Nastaran Salehi Marzijarani, Tao Wang, Eric M. Phillips, Patrick Larpent, Het P. Patel, Haiheng Guo, Xin Wang, Kangze Dai, Lu Chen, Teng Li, Taotao Lu, Jianjun Duan
  • NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN AND CRYSTALLINE PHASES OF SYNTHETIC INTERMEDIATES
    Publication number: 20220388974
    Abstract: The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2? inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.
    Type: Application
    Filed: May 20, 2022
    Publication date: December 8, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Stephen M. Dalby, Clinton Scott Shultz, Chintal Desai, Joshua Lee, Zhiwei Chen, Jungchul Kim, Nastaran Salehi Marzijarani, Tao Wang, Eric M. Phillips, Patrick Larpent, Het P. Patel, Haiheng Guo, Xin Wang, Kangze Dai, Lu Chen, Teng Li, Taotao Lu, Jianjun Duan
  • SOLID PRODRUG FORMS OF 2'-CHLORO-2'-METHYL URIDINE FOR HCV
    Publication number: 20170066795
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 9, 2017
    Applicants: IDENIX PHARMACEUTICALS LLC, Merck Sharp & Dohme Corp.
    Inventors: John Zoltan Sulliva-Bolyai, Benjamin Alexander Mayes, Douglas Lytle Mayers, Xiao-Jian Zhou, Adel M. Moussa, Alistair James Stewart, Sindhura Ganga, Clinton Scott Shultz, Alfred Lee
  • Crystal forms of a HCV protease inhibitor
    Patent number: 9242917
    Abstract: The present invention relates to different forms of a HCV inhibitory compound.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: January 26, 2016
    Assignees: Merck Sharp & Dohme Limited, Merck Sharp & Dohme Corp.
    Inventors: Gregory L Beutner, Robert M Wenslow, Jr., Eric J Choi, Clinton Scott Shultz, Jeremy Scott, Juan D Arredondo, Laura Artino
  • CRYSTAL FORMS OF A HCV PROTEASE INHIBITOR
    Publication number: 20140206605
    Abstract: The present invention relates to different forms of a HCV inhibitory compound.
    Type: Application
    Filed: August 16, 2012
    Publication date: July 24, 2014
    Inventors: Gregory L. Beutner, Robert M. Wenslow, JR., Eric J. Choi, Clinton Scott Shultz, Jeremy Scott, Juan D. Arredondo, Laura Artino
  • Process for preparing 3-chloromethyl-1,2,4-triazolin-5-one
    Patent number: 7235671
    Abstract: The present invention is directed to processes for the preparation of 3-chloromethyl-1,2,4-triazolin-5-one. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity. Also disclosed are novel semicarbazide salts and the preparation thereof, which are intermediates for the preparation of 3-chloromethyl-1,2,4-triazolin-5-one.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: June 26, 2007
    Assignee: Merck & Co. Inc.
    Inventors: Kevin Seibert, Clinton Scott Shultz, David M. Tellers